In addition to collaborating with the Jenner Institute, Merck is planning a vaccine manufacturing facility in Ghana. Credit: PRNewsfoto/MilliporeSigma

Merck subsidary MilliporeSigma has collaborated with Oxford University’s Jenner Institute to devise a robust and scalable vaccine manufacturing process to drive availability.

The main focus will be the development of adenovirus vaccines – a vaccine that uses a type of DNA virus as a delivery vehicle.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Researchers will use Merck’s technology to develop a cost-effective and transferable manufacturing process aimed at accelerating global vaccine development and production.

Merck Life Science executive board member and CEO Udit Batra said: “The collaboration with the Jenner Institute will facilitate access to affordable vaccines while improving the global response to disease outbreaks.

“Together with our partners we have shaped how vaccine production is done today and are helping to solve the toughest problems of tomorrow.”

“Such improvements should help advance the development of clinical-grade, injectable drug product for use in clinical trials and other research applications.”

The partners are aiming for a closed process that can be used in a cleanroom to reduce contamination, as part of the biological safety requirements for viral vectors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Jenner Institute director Adrian Hill said: “Merck is an excellent partner for enhancing our capabilities in adenovirus vaccine development, as the newly developed process should match or exceed our existing process in terms of productivity and purity.

“Such improvements should help advance the development of clinical-grade, injectable drug product for use in clinical trials and other research applications.”

The Jenner Institute, a partnership between the University of Oxford and the The Pirbright Institute, was founded to develop innovative vaccines against major global diseases.